What Welocalize Life Sciences does

Welo Life Sciences (formerly Welocalize Life Sciences) is a specialized translation and localization services provider serving the life sciences industry, operating as a distinct brand under parent company Welo Global. The company delivers regulator-ready translations across five core solution areas — Clinical Trials, Regulatory & Market Access, Pharmacovigilance & Post Market Surveillance, Medical Devices/IVD Labeling & IFU, and Marketing & Commercial — covering the full product lifecycle from development through post-market oversight. Its customer base consists of enterprise pharmaceutical, biotechnology, medical device, and Contract Research Organization (CRO) clients, with named reference logos including Bayer, Roche, Eli Lilly, Novartis, Medtronic, Boston Scientific, Biogen, Cochlear, Sonova, Syneos Health, Medpace, Neuraxpharm, and Fresenius.

The company's underlying technology combines AI-assisted automation with human-in-the-loop workflows under an ISO-certified quality management system. Core technical components include translation memory systems (reported to deliver 57% savings), terminology management, and integration connectors into client-side regulated platforms such as electronic Trial Master File (eTMF) systems, Quality Management Systems (QMS), and pharmacovigilance/safety platforms. The company claims 500 million cumulative words translated, 70,000 completed projects, a 99.2% on-time delivery rate, and a 99.8% compliance rate, and has received multiple AI-related industry awards between 2024 and 2026.

Welo Life Sciences generates revenue through professional services contracts under a quote-based pricing model with multi-year enterprise agreements; no public pricing tiers exist. The go-to-market motion is direct enterprise field sales with a consultative selling approach, supported by content marketing, organic SEO, and LinkedIn presence. The company serves clients worldwide and operates with a General Manager-led P&L structure under the Welo Global corporate umbrella. Cristina Pardo serves as General Manager, bringing over 20 years of localization and regulated services leadership experience.

Name

Welocalize Life Sciences

Legal name

Welo Life Sciences

Website

https://lifesciences.welocalize.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

251–500 employees

Short description

Welo Life Sciences provides ISO-certified translation and localization services for global pharmaceutical, biotech, medical device, and CRO clients across clinical, regulatory, pharmacovigilance, and commercial content workflows, operating as a brand under Welo Global.

Ownership category

akta.pro rank

Product category

Life Sciences Translation Services

NAICS

Translation and Interpretation Services (541930), Translation and Interpretation Services (54193)

SIC

Services-Health Services (8000)

akta.pro primary industry

Third-Party/Outsourced Quality & Responsible Person Services (EU QP/RP, US Agent) (HLAGAKAO)

akta.pro secondary industries

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Medical Affairs, Scientific Communications & HEOR FSP (HLAGAOAG)

Keywords

• Life sciences translation
• Clinical trial localization
• Regulatory translation services
• Pharmacovigilance translation
• Medical device labeling

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Translation and Localization Services: Provider of regulated translation and localization services for life sciences organizations, including clinical trial documentation, regulatory submissions, pharmacovigilance reports, medical device labeling, and marketing materials. Revenue is generated through professional services contracts with enterprise clients requiring multilingual content management across the product lifecycle.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Welocalize Life Sciences (operating as Welo Life Sciences) provides specialized translation and localization services for global life sciences organizations. The company delivers ISO-certified multilingual content across clinical trial documentation, regulatory submissions, pharmacovigilance reporting, medical device labeling and IFUs, and marketing/commercial communications. Services span the entire product lifecycle from development through post-market surveillance, combining hybrid AI and human workflows with subject-matter expertise for regulated environments.

Product overview

Welo Life Sciences is a unified service offering (part of Welo Global brand) providing specialized translation and language services for the life sciences industry. The portfolio consists of five integrated core solutions: Clinical Trials Solutions (for trial documentation and site activation), Regulatory & Market Access Solutions (for submissions and agency interactions), Pharmacovigilance & Post Market Surveillance (for safety reporting), Medical Devices, IVD Labeling & IFU Solutions (for technical documentation), and Marketing & Commercial Solutions (for promotional content). These solutions are delivered through ISO-certified workflows with hybrid AI and human processing, supporting the full product lifecycle from development through post-market oversight.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trials Solutions Regulator-ready translations that support IRB approvals, First Patient In, global site activation, and data integrity from day one for clinical trial documentation. Designed for CROs, pharmaceutical companies, and biotech firms managing multilingual clinical trial content across global trial networks.
• Regulatory & Market Access Solutions Precise, compliant translations aligned with global agency requirements to support regulatory submissions, responses, and ongoing regulatory interactions. Targeted at pharmaceutical and biotech companies needing multilingual submissions and consistent terminology for market access.
• Pharmacovigilance & Post Market Surveillance Fast, consistent translations and workflow support for safety reporting that keep teams inspection-ready as volumes grow. Supports pharmacovigilance teams managing safety reports, adverse event documentation, and post-market surveillance materials.
• Medical Devices, IVD Labeling & IFU Solutions Accurate, traceable translations for Instructions for Use (IFUs), in-vitro diagnostic (IVD) labeling, packaging artwork, and technical documentation that evolve alongside regulatory and post-market requirements. Targeted at medical device manufacturers.
• Marketing & Commercial Solutions Clear, compliant communications supporting launch readiness, medical education, and global engagement without compromising regulatory standards. Designed for commercial marketing teams in life sciences organizations.

Quantifiable outcome

• 99.2% on-time delivery rate
• +2 more outcomes

Named customers13 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature4 records

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• RWS Group: RWS Group is a publicly traded, large-scale language services and translation technology company with a significant Life Sciences division. Comparable in regulatory and clinical translation offerings but operates as a much broader, publicly listed incumbent.
• LanguageLine Solutions: LanguageLine Solutions is a large interpretation and translation services provider with healthcare specialization. Comparable in regulated healthcare language services, though stronger in interpretation than written life sciences translation.
• Parexel International: Parexel is a major CRO with regulatory and clinical translation capabilities embedded in its clinical research services. Competes for the same sponsor translation spend as Welo Life Sciences via integrated CRO contracts.
• ICON plc: ICON is a top-3 global CRO with translation and localization support for clinical and regulatory content. Represents a bundling-style competitive threat to dedicated LSPs like Welo Life Sciences.
• IQVIA: IQVIA is a global CRO and life sciences services giant that bundles clinical operations, regulatory, and commercial services. It overlaps indirectly with Welo Life Sciences when sponsors consolidate translation into broader CRO engagements.
• SDL (now part of RWS Group): SDL was a major language services and translation technology provider, now integrated into RWS Group. Overlaps with Welo Life Sciences on enterprise translation programs and terminology management tooling.

Direct peers

• Lionbridge Life Sciences: Lionbridge is one of the largest global language service providers with a dedicated Life Sciences vertical covering clinical, regulatory, and medical device translation. Direct overlap with Welo Life Sciences across all core solutions, customer segments, and delivery model (hybrid AI + human).
• TransPerfect Life Sciences: TransPerfect is the world's largest privately held language services company and operates a Life Sciences practice serving pharma, biotech, and medical device customers. Closely comparable in scale, customer profile, and GTM motion to Welo Life Sciences.
• AMPLEXOR (now part of Acolad): Acolad (formerly AMPLEXOR) is a European-headquartered language services group with a strong life sciences and regulatory specialization. Direct competitor in regulated translation, particularly across EU pharma customers.

Emerging players

• Smartling: Smartling is a cloud-based translation management and localization platform. While not life-sciences-specialized, it represents a technology-led adjacent competitor that could disintermediate traditional LSP workflows via automation and AI-first delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/welo-life-sciences
• Xx.com/Welocalize_LS

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Welocalize Life Sciences